ADiTx Inc (ADTX)

[jr525]

Ouch

[INFINITI]

Go ADTX$$$$

[jr525]

Lower and lower

[INFINITI]

Anything is possible my friend

[jr525]

No chance

[INFINITI]

This news should take this to dollar land

[INFINITI]

Looks good I’m in

[MT101]

Agreed

[Invest-in-America]

Agreed. I got some too. One never knows with this Medical stuff, but looks like this Company has an extremely SAFE way of doing what they do.

[jr525]

Lmao hahaha good one

[MT101]

Not at all. Will easily be $1

[jr525]

Got shut right down

[MT101]

Sorry for you. Next run just started

[jr525]

No chance..

[MT101]

Buy pressure is too high. Selling pressure is slowing now. Short squeeze formula

[jr525]

Look at it tanking already

[jr525]

Won’t touch .35 today

[MT101]

Guessing you didn’t see the news. Smh this is going to $.5 at least today. Stock should be $5-10 Low OS low Float

[jr525]

Lmao yeah ok

[MT101]

This things running! $1+ let’s go!

[kzivann]

A little news.. up premarket.. watch.

ADTX

[kzivann]

A little news.. up premarket.. watch.

ADTX

[trendzone]

Low life Algo trading program that has been run by a trading hedge fund, that has been charged with multiple violations in the past, has been the one using their algo to criminally keep the stock down, need to get squeezed and blown out.

[heyitsmeagain]

Run to 1

[heyitsmeagain]

Grabbed a load today

[jobynimble]

8-K filing…

https://www.sec.gov/ix?doc=/Archives/edgar/data/1726711/000121390022005278/ea154928-8k_aditxt.htm

Item 5.02 Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 28, 2022, Aditxt, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Matthew Shatzkes, the Chief Legal Officer and General Counsel of the Company. Pursuant to the Employment Agreement, Mr. Shatzkes will (i) receive a base salary at the annual rate of $385,000 (the “Base Compensation”) payable in bimonthly installments, (ii) receive a one-time sign-on bonus (the “Sign-on Bonus”), (iii) a minimum 2022 quarterly bonus (the “Minimum 2022 Bonus”), and (iv) will be entitled to earn an annual discretionary bonus beginning in fiscal year 2022.

Following the first anniversary of the Employment Agreement (the “Anniversary Date”), in addition to Mr. Shatzkes’ Base Compensation, Mr. Shatzkes will be entitled to a minimum quarterly bonus (the “Subsequent Year Minimum Bonus”). Following the Anniversary Date, in addition to Mr. Shatzkes’ Base Compensation and Subsequent Year Minimum Bonus, Mr. Shatzkes will also be eligible to earn an annual discretionary bonus.

Under the Employment Agreement, Mr. Shatzkes will also receive (i) a restricted stock unit award that will entitle Mr. Shatzkes to receive 150,000 shares of the Company’s common stock which shall vest immediately, and (ii) a restricted stock unit award of an additional 330,000 shares of the Company’s common stock, which shall vest ratably over eight successive equal quarterly installments over a two-year period commencing on March 1, 2022 and ending on December 1, 2023.

The term of Mr. Shatzkes engagement under the Employment Agreement commences on the Effective Date (as defined in the Employment Agreement) and continues until January 16, 2024, unless earlier terminated in accordance with the terms of the Employment Agreement. The term of Mr. Shatzkes’ Employment Agreement is automatically renewed for successive one-year periods until terminated by Mr. Shatzkes or the Company.

Under the Employment Agreement, termination of Mr. Shatzkes by the Company for “Cause,” “Death,” or “Disability,” (as such terms are defined in the Employment Agreement), or resignation by Mr. Shatzkes without “Good Reason” (as defined in the Employment Agreement), will not require the Company to pay severance to Mr. Shatzkes. Upon any such termination, Mr. Shatzkes will be entitled to receive any Accrued Compensation (as defined in the Employment Agreement), which in the case of termination by the Company for Cause or resignation by Mr. Shatzkes for Good Reason will not include payment of pro rata bonus. If, however, termination of Mr. Shatzkes by the Company without “Cause”, resignation by Mr. Shatzkes for “Good Reason” or and a Change of Control (as defined in the Employment Agreement) event occurs, then the Employment Agreement will require the Company to pay severance to Mr. Shatzkes. Upon any such termination, Mr. Shatzkes will be entitled to receive any Accrued Compensation and, subject to Mr. Shatzkes’ execution of an irrevocable release, (i) on the sixtieth day following termination, a lump sum amount equal (a) twelve months of his Base Compensation, Sign-on Bonus and Minimum 2022 Bonus if his Employment Agreement is terminated prior to December 31, 2022, or (b) his Base Compensation and Subsequent Year Minimum Bonus if his Employment Agreement is terminated after December 31, 2022; (ii) provide reimbursement to Mr. Shatzkes’ medical insurance premiums for a period of twelve months following the date of termination; and (iii) notwithstanding any provision of any stock incentive plan, stock option agreement, realization bonus, restricted stock agreement or other agreement relating to capital stock of the Company, cause any equity awards granted prior to that termination that are then outstanding and unvested to immediately vest and, with respect to all options and stock appreciation rights, to become fully exercisable.

To the extent any of the payments or benefits provided for under the Employment Agreement or any other agreement or arrangement between Mr. Shatzkes and the Company (collectively, the “Payments”), (a) constitute an “excess parachute payment” within the meaning of Section 280G (“Section 280G”) of the Internal Revenue Code of 1986, as amended and restated (the “Code”), and (b) would otherwise be subject to the excise tax imposed by Section 4999 of the Code (“Section 4999”), then the Company will pay or provide the greater (whichever gives Mr. Shatzkes the highest net after-tax amount) of (i) all of the Payments or (ii) the portion of Payments not in excess of the greatest amount of Payments that can be paid that would not result in the imposition of the excise tax under Section 4999.

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety to the full text of the Employment Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

[jobynimble]

ADTX delisting notice…

https://www.sec.gov/ix?doc=/Archives/edgar/data/1726711/000121390022003076/ea154276-8k_aditxtinc.htm

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 18, 2022, Aditxt, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock between December 1, 2021 and January 14, 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol “ADTX.”

The Notification Letter provides that the Company has 180 calendar days, or until July 18, 2022, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July 18, 2022, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

The Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

[station1111]

Run to $1.oo. $$$$

[jobynimble]

Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO

January 12 2022 - 09:00AM
Business Wire

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.

The upcoming meeting will include, but is not limited to, commentary on the following topics:

A business update and upcoming milestones
A summary and discussion of revenue strategy
An overview of the acquisition strategy
The online meeting will be followed by Q&A. All investors are invited to attend, whether professional or individual.

All questions can be submitted in advance via email: [e-mail].

To join the webinar, CLICK HERE Or paste the link directly into your browser:

https://edisongroup.zoom.us/webinar/register/WN_fuO3kop7RqaETiLhfzzqyA

About Aditxt™

Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile. Aditxt’s immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile technology to equip people with information about their level of protection. For more information, please visit: www.aditxt.com and www.AditxtScore.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. All statements other than historical fact contained in this press release, including, without limitation, statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development, revenue strategy and acquisition strategy; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company, are forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other essential factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.


View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005412/en/

Media and Investor Relations Contact:
Edison Investment Research
[e-mail]

[station1111]

drop down to .40 and your mine. $$$

[station1111]

Took a small position at .64, down only a few pennies so far for 2022. Still in the first inning in a 9 inning game...lol

[Awl416]

Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use

[oxnous]

Adding Aditxt (ADTX) to the upcoming “2022 Biotech 6-Pack, Stocks We Expect to Double” Watch List.

We’re sitting in a hotel room in Chicago minding our own business – then as has happened nearly every year since 1987 when we first started hunting for ‘indiscriminate’ tax-loss candidates the last week of the year – BOOM – Aditxt gets banged and but good. And with enough volume for speculators to grab a meaningful stake. 7 million shares traded so far.

Yes, it’s a weird name, but we saw their presentation at an investor conference and loved what we heard. Then we had lunch with the CEO Amro Albanna the next day,and loved it even more.

Something though told us to wait.

[Flyfire13]

Going to surpass 10 day avg vol with ease

[RUSTYJ]

Can anyone tell me whats going on here???

[mik1234]

ADTX it was 5.85 USD Aug 7, 2020

[mik1234]

Watching it Volume: 3,333,023 @12/13/21 12:55:01 PM EST

[ErnieBilco]

Could be, I've never heard of the ticker before the smackdown and that's the only reason I bought, I don't really care what they have or don't have in their pipeline, I'm just betting we see $1.25 short term.

[jobynimble]

Worst time of the year to do an offering like this, positioning now should see a nice pop after tax loss selling is over, so we might have to wait til January to see it…

[ErnieBilco]

Nice spot to grab a starter on this.

Offering is $1.05 with a warrant so I feel good buying down here in the .87s.

[420man]

Bid .50... Offering likely priced around .75.

[MASTERULTRA]

On Nov. 12th, 2021.

ADITX has reached to a definitive agreement with AI Pharma (generate $150 mil in 2021). Will be closing by end of NOV. 30th, 2021.


This is a BIG DEAL...

[MASTERULTRA]

Merger closing after today.

[jobynimble]

Expecting news?

[MASTERULTRA]

Hope this opens at $5/per shares tomorrow.

[jobynimble]

4th…

[jobynimble]

Link to all SEC filings: https://www.sec.gov/edgar/browse/?CIK=1726711&owner=exclude

[jobynimble]

8-K filing today…

Item 1.01 Entry into a Material Definitive Agreement.

On November 24, 2021, Aditxt, Inc. (the “Company”) entered into a Warrant Reduction and Release Agreement (the “Warrant Reduction Agreement”) with certain investors (the “Investors”) that are the holders of warrants (the “Warrants”) issued in connection with the Securities Purchase Agreement dated as of August 25, 2021 by and between the Company and each of the Investors (the “Purchase Agreement”). Pursuant to the Warrant Reduction Agreement, the Company agreed to reduce the exercise price of the Warrants to $1.50 per share and to provide the Investors with a right to participate in certain future financings of the Company in consideration of the parties agreeing to certain mutual releases.

The foregoing description of the form of Warrant Reduction Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Warrant Reduction Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Full filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1726711/000121390021061795/ea151351-8k_aditxtinc.htm

[jobynimble]

The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders

November 22 2021 - 09:00AM
Business Wire

AditxtScore™ will be used for Assessing Immune Status for COVID-19

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company that improves the health of the immune system, announced today that the Johnson County Sherriff’s Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore™ for assessing the immune status for COVID-19 in its employees.

AditxtScore™ is an immune monitoring platform which provides a personalized and comprehensive profile of the immune system. AditxtScore™ for COVID-19 helps to answer the growing need for a personalized approach to combating the pandemic. AditxtScore™ further differentiates itself by quantitatively measuring the strength of an individual’s immune response to the novel coronavirus with high precision, helping patients and their providers make informed decisions for a proper course of action.

Sheriff Calvin Hayden commented, “If an individual’s antibodies are low, they may decide to get the vaccine or a booster. Alternatively, if their antibodies are high, either due to natural infection or from the vaccine, it may be best for them to wait on the booster. With their AditxtScore™, they will finally have the information to guide these important health decisions – information they do not currently have. Informed individuals are empowered to make healthy decisions.” He added, “The Johnson County Sheriff's Office has done a stellar job of managing COVID-19. We haven’t skipped a beat in the services we’ve provided, and the AditxtScore™ immune profile takes it to the next level.”

“AditxtScore™ provides meaningful information to help understand one’s personal immune response to COVID-19 and not just that of the population collectively,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. Aditxt’s immune monitoring platform is a pioneering approach to the health of our immune system. “Precision immunotherapies can only be effectively developed when we have a better understanding of the immune system. This understanding is the guiding principle of AditxtScore™,” Amro added. “AditxtScore™ for COVID-19 application provides an opportunity to assess the immunity status in response to COVID-19 by measuring levels of multiple antibody isotypes (IgM, IgG and IgA) that can develop against components of the spike protein encoded by current vaccines, as well as additional viral proteins that can be produce in response to natural infection. Additionally, measurement of the neutralizing capabilities of these antibodies further illustrates the effectiveness of the immune response to help protect against future infections.”

Dave Owen, President of KanVest Services, an Aditxt channel partner and advisor to the Johnson County Sherriff’s Office, commented, “AditxtScore™ provides a unique, precise, and comprehensive test that delivers so much more than simply a ‘negative’ or ‘positive’ test result, as with standard antibody tests. Just as not all people are alike in how their bodies respond to the virus and/or the vaccine, not all antibody tests are alike. How are individuals to know if they have a ‘high protective level of antibodies’ or ‘low at-risk level of antibodies’ or ‘no antibodies’ given the fact that most tests on the market simply indicate ‘yes, you have some antibodies’, or ‘no, you do not have antibodies’. We are proud to be a channel partner of Aditxt and distribute the AditxtScore™ for COVID-19. It equips individuals with their personal immune profile so they can make informed decisions about their health. The AditxtScore™ immune monitoring tool is an essential component for the public and private sectors, managing through the COVID-19 pandemic.”

About Aditxt™

Aditxt develops technologies focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology, currently in the preclinical state, is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile technology to equip people with information about their personal level of protection. For more information, please visit: www.aditxt.com www.AditxtScore™.com

About KanVest Services

KanVest Services is a healthtech company that provides products and services that support preventive health, for the public and private sectors across the US. KanVest is a national distributor of AditxtScore™ for COVID-19, a comprehensive immune profile that measures the strength of an individual’s immune response to COVID-19, so they can make informed decisions with the optimal course of action for their health, to better navigate the global pandemic. …getting America back to normal with confidence– using science. www.Kanvest.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006231/en/

Media and Investor Relations Contact:
Aditxt, Inc.
[e-mail]

[$Pistol Pete$]

Thanks Brother